CCR6 and diabetes mellitus: Further validation of the therapeutic efficacy of resveratrol in diabetes was shown by the accumulation of IL-17 –producing cells and CD11b+F4/80high macrophages in the spleen and pancreatic lymph nodes but not in the pancreas itself, suggesting that resveratrol blocks CCR6 signaling and prevents migration of CCR6-bearing immune cells from peripheral lymphoid organs to the pancreas.